The New predictiVe factors that drIve coronary atheroscleroSIs follOwiNg Coronary Artery Disease (VISION-CAD)” study

South Australian Health and Medical Research Institute0 个研究点目标入组 300 人开始时间: 2023年5月3日最近更新: 2024年7月29日

适应症

试验速览

暂无简介。

•Subjects who have received a clinically indicated coronary angiogram for stable or unstable CAD, including stable angina, unstable angina and acute myocardial infarction (MI), comprising non-ST elevation MI (NSTEMI) or ST-elevation MI (STEMI).
•All subjects will be managed as per their treating clinicians, including with percutaneous coronary intervention (PCI) where indicated and use of antiplatelets, lipid-lowering medication (e.g. statins) and other guideline-recommended therapies.
•Eligible subjects will be those who at the time of angiography are identified as having at least one major coronary artery system (left main, left anterior descending, left circumflex, ramus intermedius or right coronary artery) that will be left with residual coronary plaque with no intention to revascularise this by PCI or bypass grafting for at least the next 12 months. Age 18 years or more at the time of screening.
•Able to provide informed consent to undergo non-invasive CTCA imaging within 30 days of their index angiogram and return for a follow-up CTCA 12±1 months later.
•Willingness to provide a blood sample (50 mL) around the time of their baseline and follow-up CTCA, and attend for an additional face-to-face study visit or receive a phone call at 6 months.

•Any associated co-morbidity in which the life expectancy is <1 year.
•Dialysis or estimated glomerular filtration rate (eGFR) <30 ml/min/1.73m2
•Previous or planned coronary artery bypass grafting
•Active malignancy with ongoing or planned chemotherapy or radiation therapy
•Contraindications to CTCA
•Women of childbearing potential who are not partaking in contraception
•Unable to give informed consent
•Not willing or able to attend follow-up visits/repeat CTCA in 12 months
•Concurrent enrollment in a placebo-controlled trial or within 30 days of finishing a trial
•Any other information that the investigators consider will limit the ability of the participant to complete all study associated procedures and visits

发起方